RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Latest Information Update: 17 Sep 2026
At a glance
- Drugs Selcodebart (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms RALLY-MF
- Sponsors Disc Medicine
Most Recent Events
- 20 Jul 2026 Planned End Date changed from 1 Sep 2026 to 1 Jun 2027.
- 20 Jul 2026 Planned primary completion date changed from 1 Sep 2026 to 1 May 2027.
- 12 Jun 2026 Results published in the Media Release